• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA expands indication for On-X Life’s heart valve

FDA expands indication for On-X Life’s heart valve

April 3, 2015 By Mark Hollmer

FDA expands indication for On-X Life's heart valve

On-X Life Technologies said it nailed down an expanded labeling claim from the FDA for its aortic mechanical heart valve.

The change relates to an international normalized ratio blood test, which measures the length of time needed for a patient’s blood to clot. Regulators expanded the label to allow the Texas company’s aortic heart valve to be managed, beginning 3 months after surgery, at an INR level of 1.5 to 2.0 – closer to the ratio of unmedicated patients.

On-X said it won the change following the results of the company’s Proact trial, published in 2014 in the Journal of Thoracic and Cardiovascular Surgery, which showed high-risk patients with the On-X aortic valve saw less bleeding and no jump in stroke rates when they reduced their regular blood-thinning medication dosage to an INR of 1.5 to 2.0, and also took low-dose aspirin.

On-X CEO Clyde Baker said in prepared remarks that the "newly-approved expanded labeling, which lowers the recommended INR rates for On-X aortic valves, reinforces how our technology represents a single-life-long clinical solution that frees patients of worries of potential reoperation due to tissue valve failure.”

On-X founder Jack Bokros added, also in a prepared statement, that the FDA expanded labeling represented validation of a 50-year retrospective study of mechanical heart valves from 2014 that showed On-X’s pyrolytic carbon valves produced the lowest documented rate of clots versus 8 other competing products.

The company is using the FDA decision to tout its product’s benefits over valve replacements made with animal tissue, which some patients choose in order to avoid having to deal with side effects from blood-thinning medications such as warfarin.

Baker noted that tissue valves tend to fail within 15 years and carry the risk of subsequent operations for replacement valves. These patients must also frequently take warfarin, he said.

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance, Replacement Heart Valves Tagged With: On-X Life Technologies

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy